FDA Panel Backs BPC-157 and TB-500 — but Rejects Emideltide (DSIP). What It Actually Means

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) took up seven peptides — including two of the most-discussed compounds in the space, BPC-157 and TB-500 — and recommended one after another for the 503A bulks list.

It did so over the objection of the FDA’s own scientists, who had recommended against all seven. That is the genuinely unusual part, and it is why this landed on the front page of NPR, STAT, NBC and TIME rather than in a trade newsletter.

Then, on day two, the streak broke. Emideltide — better known as DSIP, the delta sleep-inducing peptide — was voted down 6–7 with one abstention, the first and so far only substance the panel declined to recommend. That rejection is arguably more informative than any of the approvals, because it shows the committee was drawing a line somewhere.

It is also being widely misread. This vote is not an approval, it is not binding, and nothing at your pharmacy changed this week. Here is what actually happened and what has to occur before anything does.

What the panel voted on

The question before the committee was narrow: should each substance be added to the 503A bulks list — the set of bulk drug substances that state-licensed compounding pharmacies may legally use to prepare a medication for an individual patient?

Note how narrow the margins were. A one- or two-vote swing would have flipped several of these — and on emideltide, that is exactly what happened. This was not a consensus endorsement of anything; it was a divided committee that came down, mostly but not always, on the permissive side.

The one that failed: why emideltide (DSIP) went down

Emideltide is the compounding-world name for DSIP, the delta sleep-inducing peptide — a nine-amino-acid neuropeptide first isolated in 1974 and nominated here for subcutaneous use in insomnia. The panel rejected it 6–7 with one abstention. Understanding why is the most useful thing in this whole meeting.

The FDA’s objection went further than the generic "not enough evidence" it raised against everything else. Reviewers flagged that emideltide’s sleep and analgesic effects appear to run through opioid-dependent endorphin release — and that no nonclinical work had characterized whether that mechanism carries addictive liability. That is a specific, mechanistic safety concern, not a data-volume complaint.

On top of that, the human evidence was both old and thin — small placebo-controlled insomnia studies from the 1980s with single-digit to low-double-digit sample sizes and mixed results — and what existed was largely intravenous, while the nomination sought the subcutaneous route. Reviewers also flagged inconsistent naming conventions and missing characterization data across the two proposed forms.

Read against the rest of the meeting, the pattern is legible: this panel was willing to defer to physician and pharmacist judgment on compounds with thin efficacy data, but not on one with an unexamined dependence signal. Whatever you make of the other six votes, that is a real distinction rather than a rubber stamp.

Why the FDA’s own scientists said no

Agency staff recommended against every substance, and their reasoning matters more than the vote count — because the FDA, not the panel, makes the final call.

The first objection was evidence. The briefing materials pointed to a single BPC-157 trial involving 46 people, and no human studies at all supporting KPV. Committee member Elizabeth Rebello pressed the point directly, citing the lack of efficacy data and randomized controlled trials.

The second objection is the harder one, and it is easy to miss: the agency could not reliably say what these substances are. Several lack a universally accepted chemical definition. As one official put it, the FDA had never before confronted the problem of "What is it?" Without a settled characterization, you cannot write meaningful quality, purity, or potency standards — which is the entire basis on which a compounding pharmacy would be held accountable.

The counterargument carried the day anyway. Committee member David Pope argued it was "time to put this decision back in the hands of the physician and pharmacist" — the view that people are already using these compounds, and a regulated pharmacy is safer than the alternative. Supporters explicitly framed the choice as pharmacy access versus consumers sourcing from unregulated overseas suppliers.

What the vote does not mean

Four corrections, in rough order of how often they are getting mangled online this week.

1. This is not FDA approval. Approval means clinical trials establishing safety and efficacy for a defined indication. None of these peptides have that, and this process would not give it to them. Even in the best case they remain unapproved drugs that a pharmacy may compound.
2. The vote is not binding. PCAC advises; the FDA decides. The agency has gone against this committee before, and here it is being asked to overrule its own staff scientists to do so.
3. Nothing is legal yet. The pathway runs: removal from Category 2, the advisory recommendation, then formal notice-and-comment rulemaking to reach Category 1. Legal analysts put the realistic timeline at eight to twelve months before pharmacies have unambiguous authority — assuming the FDA agrees at all.
4. It does not touch "research use only" vendors. The 503A pathway is about licensed pharmacies filling prescriptions. Grey-market material sold online is unaffected, and would remain outside the regulated supply chain even if every one of these substances is eventually listed.

The conflict-of-interest question

STAT News reported that a majority of the panelists who voted yes have ties to the peptide industry. That does not by itself invalidate the votes — advisory committees routinely seat members with domain experience, which tends to correlate with industry connections — but it is a material fact in weighing how much the recommendation should count, and the FDA will be weighing it too.

The emideltide rejection cuts against the simplest version of that critique. A panel purely captured by industry does not vote one of the nominations down on a mechanistic safety concern. It is fairer to read this as a committee with a low bar that emideltide still failed to clear.

The vote is also being read politically. Coverage has framed it as a win for Health Secretary Robert F. Kennedy Jr., who has favored broader peptide access. That framing raises the stakes on the agency’s eventual response: following the panel and overruling its own scientists would be a notable departure from how these decisions usually go.

What this changes for you right now

Practically: nothing this week. Legally, your situation on July 25 is identical to July 22. What has changed is the probability distribution over the next year — and that is worth preparing for rather than acting on.

• Do not treat this as a green light. The single most common error being made right now is reading "advisory panel voted yes" as "it is approved." It is neither approved nor yet legal to compound.
• If a vendor cites this vote as validation, be more skeptical, not less. A non-binding recommendation that the FDA’s own scientists opposed is a strange thing to market on, and anyone doing so is telling you how they read evidence.
• A pharmacy route would be a real change in what you are taking. If listing eventually happens, compounded material from a licensed pharmacy differs from grey-market material in identity, purity, and concentration. That is a protocol change, and it is only interpretable against a documented baseline.
• Write down your baseline now. Whatever you are currently running, a clean record of dose, source, and response is what makes any future switch measurable instead of guesswork.

Next up: five more peptides by February 2027

This week was only the first of two scheduled sessions. The FDA has committed to convening the PCAC again before the end of February 2027 to consider five additional substances for the same 503A bulks list.

No exact date has been published yet — expect a Federal Register notice a couple of months ahead of the meeting. If this week set the pattern, the FDA’s reviewers will again recommend against the full slate, and the interesting question will be whether the committee keeps overruling them or whether emideltide marked the point where it started drawing lines.

What to watch next

Three things will tell you whether this becomes real:

• Whether the FDA follows the panel. The agency has no deadline to respond. Silence is not agreement.
• Whether a proposed rule is published. Until a substance appears in a notice-and-comment rulemaking for Category 1, nothing has legally moved.
• The separate 503B track. A different question — whether large outsourcing facilities can compound GLP-1s — is running in parallel. The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with the comment period extended to July 30, 2026. We cover that in our 2026 FDA approvals roundup.

Two tracks, opposite directions: the peptide side loosening, the GLP-1 side tightening. Both are unresolved, and both are worth following without getting ahead of them.

Frequently asked questions